Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Yidafan (ivonescimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Akesobio, Summit Therapeutics

Drug class:

PD1 inhibitor, VEGF inhibitor

Related drugs:

‹

pembrolizumab (727)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (6)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1-KO-T cell injection (0)

PF-07209960 (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

recombinant human endostatin (5)

autologous activated lymphocytes (0)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ivonescimab Sensitive: B - Late Trials ivonescimab Sensitive : B	ivonescimab Sensitive: B - Late Trials ivonescimab Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3